Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics hits enrolment target for Phase 2 trial of anti-cancer drug

Viralytics hits enrolment target for Phase 2 trial of anti-cancer drug

Viralytics (ASX: VLA, OTCQX:VRACY) has achieved the target enrolment for the Phase 2 melanoma trial for its CAVATAK anti-cancer drug for the treatment of late stage melanoma.

The 54th patient has been injected with the drug while interim results show that 14 of the 40 evaluable patients reaching the six month immune related Progression Free Survival target.

In addition, there is promising one year survival data with 12 of first 20 patients still alive at that stage.

The Phase 2 trial is a single arm study being conducted at 11 US cancer clinics to investigate the safety and efficacy of intratumoral CAVATAK in patients with late stage malignant melanoma.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Woman stroking face
October 03 2017
Its SkinBiotix cream was assessed for cellular toxicity
test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use